Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and skyping has, of course, returned. What else to do but fire up the coffee kettle for a cup of stimulation and dig in. On that note, we bring you the latest round of tidbits and hope these help you on your journey. Have a splendid day and do keep in touch. …

Gilead Sciences (GILD) increased the U.S. prices of many of its major products on March 16 by 4.9 percent, including all of its HIV medications, but excluding its hepatitis C treatments and the Yescarta CAR-T therapy, according to Cowen analyst Phil Nadeau. He explains price hikes are “consistent with Gilead’s historical practice,” since the drug maker has typically raised prices once per year during the first quarter. He adds that Gilead will not recognize the full magnitude of the price increases because of discounts, rebates, and regulations.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy